Lynne Davies

Lynne Davies

Auto-generated profile, based on publicly available information

Lynne Davies

International Cancer Research Partnership, Cardiff, United Kingdom

Research Focus & Metrics

Academic Career Length

34Years (1993-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 1996 in British Journal of Haematology
Verified
Journal Article
Closed access
DGDavid Grimwade
David Grimwade
KHKathy Howe
Kathy Howe
SLStephen Langrbeer
Stephen Langrbeer
LDLynne Davis
Lynne Davis
FOFiona Oliver
Fiona Oliver
ESEllen Solomon
Ellen Solomon

1 October 1993 in Cell
Verified
Journal Article
Closed access
LDLynne Davies
Lynne Davies
MSMichel Satre
Michel Satre
JMJean-Baptiste Martin
Jean-Baptiste Martin
JGJulian D. Gross
Julian D. Gross

1 December 2021 in JCO Global Oncology
Verified
Journal Article
Open access
RARachel Abudu
Rachel Abudu
GBGauthier Bouche
Gauthier Bouche
KBKarima Bourougaa
Karima Bourougaa
LDLynne Davies
Lynne Davies
KDKalina Duncan
Kalina Duncan
KWKari Wojtanik
Kari Wojtanik
The International Cancer Research Partnership (ICRP) is an active network of cancer research funding organizations, sharing information about funded research projects in a common database. Data are publicly available to enable the cancer research community to find potential collaborators and avoid duplication. This study presents an aggregated analysis of projects funded by 120 partner organizations and institutes in 2006-2018, to highlight trends in cancer research funding. Overall, the partners’ funding for cancer research increased from $5.562 billion (bn) US dollars (USD) in 2006 to $8.511bn USD in 2018, an above-inflation increase in funding. Analysis by the main research focus of projects using Common Scientific Outline categories showed that Treatment was the largest investment category in 2018, followed by Early Detection, Diagnosis, and Prognosis; Cancer Biology; Etiology; Control, Survivorship, and Outcomes; and Prevention. Over the 13 years covered by this analysis, research funding into Treatment and Early Detection, Diagnosis, and Prognosis had increased in terms of absolute investment and as a proportion of the portfolio. Research funding in Cancer Biology and Etiology declined as a percentage of the portfolio, and funding for Prevention and Control, Survivorship and Outcomes remained static. In terms of cancer site–specific research, funding for breast cancer and colorectal cancer had increased in absolute terms but declined as a percentage of the portfolio. By contrast, investment for brain cancer, lung cancer, leukemia, melanoma, and pancreatic cancer increased both in absolute terms and as a percentage of the portfolio.

6 October 1996 in Molecular Microbiology
Verified
Journal Article
Closed access
PDF file
LDL. Davies
L. Davies
NFN. A. Farrar
N. A. Farrar
MSM. Satre
M. Satre
RDR. P. Dottin
R. P. Dottin
JGJ. D. Gross
J. D. Gross

1 June 2023 in JCO Global Oncology
Verified
Journal Article
Open access
LDLynne Davies
Lynne Davies
DMDanny A. Milner
Danny A. Milner
LSLawrence N. Shulman
Lawrence N. Shulman
LKLynnette Kyokunda
Lynnette Kyokunda
ABAlemayehu Bedada
Alemayehu Bedada
UDUte Dugan
Ute Dugan
PURPOSE: To evaluate the scope and types of cancer research projects in sub-Saharan Africa (SSA) to identify research gaps and inform future efforts. METHODS: This retrospective observational study summarized information on cancer research projects in SSA from the International Cancer Research Partnership (ICRP) between 2015 and 2020, alongside 2020 cancer incidence and mortality data from the Global Cancer Observatory. SSA cancer research projects were identified as led by investigators in SSA countries, or by investigators in non-SSA countries with collaborators in SSA, or in database keyword searches. Projects from the Coalition for Implementation Research in Global Oncology (CIRGO) were also summarized. RESULTS: A total of 1,846 projects were identified from the ICRP database, funded by 34 organizations in seven countries (only one, Cancer Association of South Africa, based in SSA); only 156 (8%) were led by SSA-based investigators. Most projects focused on virally induced cancers (57%). Across all cancer types, projects were most frequently related to cervical cancer (24%), Kaposi sarcoma (15%), breast cancer (10%), or non-Hodgkin lymphoma (10%). Gaps were observed for several cancers with higher incidence/mortality burden in SSA; for example, prostate cancer accounted for only 4% of projects but 8% of cancer-related deaths and 10% of new cases. Approximately 26% were dedicated to etiology. Treatment-related research declined over the study period (14%-7% of all projects), while projects related to prevention (15%-20%) and diagnosis/prognosis (15%-29%) increased. Fifteen CIRGO projects were identified; seven were relevant across multiple cancer types, and 12 focused either wholly or partially on cancer control (representing 50% of the total research effort). CONCLUSION: This analysis shows notable discrepancies between cancer burden and research projects and identifies opportunities for future strategic investments in cancer care in SSA.

1 April 2017 in Gastroenterology
Verified
Journal Article
Closed access
PDF file
AHAndrew E. Hendifar
Andrew E. Hendifar
LDLynne Davies
Lynne Davies
RTRichard Tuli
Richard Tuli